{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:32:59Z","timestamp":1793154779589,"version":"4.5.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Coronavirus disease 2019 (COVID-19) has been associated with an increased thrombotic risk, potentially exacerbated in patients with active cancer. We conducted a retrospective cohort study including 119 cancer patients with COVID-19 and 214 matched prepandemic controls. Patients with COVID-19 had poorer performance status and were more frequently treated with palliative intent. After a median follow-up of 32.7\u2009months, overall thrombotic event rates did not differ between groups. However, after adjustment for clinically relevant covariates and accounting for death as a competing event, COVID-19 status and palliative treatment intent remained independently associated with a higher cumulative incidence of thrombotic events. In conclusion, COVID-19 may increase thrombotic risk in patients with cancer and occurs more frequently in patients with poorer clinical status. These findings are exploratory and require confirmation in larger prospective studies.<\/jats:p>","DOI":"10.1093\/jncics\/pkag110","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:47:40Z","timestamp":1791460060000},"source":"Crossref","is-referenced-by-count":0,"title":["COVID-19 and thrombotic risk in patients with active cancer: a matched cohort study"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4646-4778","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Doyen","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Antoine Lacassagne Cancer Center, C\u00f4te d\u2019Azur University , Nice,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Lacour","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Centre Hospitalier Universitaire de Nice , Nice,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Schiappa","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Biostatistics and Health Data, Centre Antoine-Lacassagne, C\u00f4te d\u2019Azur University , Nice,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Seutin","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Biostatistics and Health Data, Centre Antoine-Lacassagne, C\u00f4te d\u2019Azur University , Nice,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Garrido","sequence":"additional","affiliation":[{"name":"ICBMS\u2014Institut de Chimie et de Biochimie Mol\u00e9culaires et Supramol\u00e9culaires, Equipe COSSBA UMR 5246 , Lyon,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanguy Pace","family":"Loscos","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Biostatistics and Health Data, Centre Antoine-Lacassagne, C\u00f4te d\u2019Azur University , Nice,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Doyen","sequence":"additional","affiliation":[{"name":"Unit\u00e9 d\u2019Explorations Fonctionnelles, Centre Hospitalier Universitaire de Nice, C\u00f4te d'Azur University , Nice,","place":["France"]},{"name":"LP2M, Laboratoire de Physiom\u00e9decine Mol\u00e9culaire, CNRS, C\u00f4te d\u2019Azur University , Nice,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"2026102722070586100_pkag110-B1","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1136\/thoraxjnl-2020-216243","article-title":"COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms","volume":"76","author":"Loo","year":"2021","journal-title":"Thorax"},{"key":"2026102722070586100_pkag110-B2","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1161\/CIRCULATIONAHA.122.060785","article-title":"Association of COVID-19 with major arterial and venous thrombotic diseases: a population-wide cohort study of 48 million adults in England and Wales","volume":"146","author":"Knight","year":"2022","journal-title":"Circulation"},{"key":"2026102722070586100_pkag110-B3","doi-asserted-by":"publisher","first-page":"e1001275","DOI":"10.1371\/journal.pmed.1001275","article-title":"Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis","volume":"9","author":"Horsted","year":"2012","journal-title":"PLoS Med"},{"key":"2026102722070586100_pkag110-B4","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkac063","article-title":"Methodological considerations on COVID-19 mortality in cancer patients: a systematic review and meta-analysis","volume":"6","author":"Zewde","year":"2022","journal-title":"JNCI Cancer Spectr"},{"key":"2026102722070586100_pkag110-B5","doi-asserted-by":"publisher","first-page":"e2210880","DOI":"10.1001\/jamanetworkopen.2022.10880","article-title":"Differences in outcomes and factors associated with mortality among patients with SARS-CoV-2 infection and cancer compared with those without cancer: a systematic review and meta-analysis","volume":"5","author":"Khoury","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026102722070586100_pkag110-B6","doi-asserted-by":"publisher","first-page":"e069590","DOI":"10.1136\/bmj-2021-069590","article-title":"Risks of deep vein thrombosis, pulmonary embolism, and bleeding after COVID-19: nationwide self-controlled cases series and matched cohort study","volume":"377","author":"Katsoularis","year":"2022","journal-title":"BMJ"},{"key":"2026102722070586100_pkag110-B7","doi-asserted-by":"publisher","first-page":"100284","DOI":"10.1016\/j.rpth.2023.100284","article-title":"Pulmonary embolism and deep venous thrombosis after COVID-19: long-term risk in a population-based cohort study","volume":"7","author":"Sjoland","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"2026102722070586100_pkag110-B8","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1056\/NEJMp2015897","article-title":"False negative tests for SARS-CoV-2 infection\u2014challenges and implications","volume":"383","author":"Woloshin","year":"2020","journal-title":"N Engl J Med"},{"key":"2026102722070586100_pkag110-B9","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"2026102722070586100_pkag110-B10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-x","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"key":"2026102722070586100_pkag110-B11","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1200\/JCO.20.01580","article-title":"COVID-19 severity and outcomes in patients with cancer: a matched cohort study","volume":"38","author":"Brar","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026102722070586100_pkag110-B12","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1111\/jth.15018","article-title":"Incidence of thrombosis and hemorrhage in hospitalized cancer patients with COVID-19","volume":"18","author":"Patell","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2026102722070586100_pkag110-B13","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jamaoncol.2023.2934","article-title":"Systemic anticancer therapy and thromboembolic outcomes in hospitalized patients with cancer and COVID-19","volume":"9","author":"Gulati","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026102722070586100_pkag110-B14","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.21873\/anticanres.15815","article-title":"Thromboembolic disease in patients with cancer and COVID-19: risk factors, prevention and practical thromboprophylaxis recommendations-state-of-the-art","volume":"42","author":"Dimakakos","year":"2022","journal-title":"Anticancer Res"},{"key":"2026102722070586100_pkag110-B15","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMoa2105911","article-title":"Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19","volume":"385","author":"Lawler","year":"2021","journal-title":"N Engl J Med"},{"key":"2026102722070586100_pkag110-B16","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1001\/jamainternmed.2021.6203","article-title":"Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial","volume":"181","author":"Spyropoulos","year":"2021","journal-title":"JAMA Intern Med"},{"key":"2026102722070586100_pkag110-B17","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/S0140-6736(20)31173-9","article-title":"COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study","volume":"395","author":"Lee","year":"2020","journal-title":"Lancet"},{"key":"2026102722070586100_pkag110-B18","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1158\/1078-0432.CCR-15-1849","article-title":"Reversing T-cell dysfunction and exhaustion in cancer","volume":"22","author":"Zarour","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026102722070586100_pkag110-B19","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T cell dysfunction in cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"key":"2026102722070586100_pkag110-B20","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1056\/NEJMoa1210384","article-title":"Low-dose aspirin for preventing recurrent venous thromboembolism","volume":"367","author":"Brighton","year":"2012","journal-title":"N Engl J Med"}],"container-title":["JNCI Cancer Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncics\/advance-article-pdf\/doi\/10.1093\/jncics\/pkag110\/71877583\/pkag110.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/10\/5\/pkag110\/71877583\/pkag110.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/10\/5\/pkag110\/71877583\/pkag110.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:07:15Z","timestamp":1793153235000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncics\/article\/doi\/10.1093\/jncics\/pkag110\/8910656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jncics\/pkag110","relation":{},"ISSN":["2515-5091"],"issn-type":[{"value":"2515-5091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,3]]},"article-number":"pkag110"}}